3- (5'- hydroxymethyl- 2'- furyl)- 1- benzylindazole (YC 1)

10/01/2009 - "On the basis of the reported role of YC-1 as a HIF-1 inhibitor with anti-cancer activity, we tested the therapeutic efficacy of YC-1 against radioresistance in vitro. "
01/01/2013 - "3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1), a novel anticancer drug initially developed as an inhibitor of HIF-1α, is currently undergoing preclinical trials against various forms of cancer. "
03/01/2005 - "In a corollary in vivo study, YC-1 induced dose-dependent inhibition of tumor growth in mice inoculated with HA22T cells. "
07/21/2015 - "Moreover, ectopic expression of STIM1 or HIF-1α partially reverses impaired growth of tumors treated with YC-1. "
09/01/2014 - "YC-1 exhibits potent anticancer activity via numerous actions in many cancer cell lines. "

03/01/2005 - "This study delineates the antiproliferative activities and in vivo efficacy of YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] in human hepatocellular carcinoma cells. "
10/06/2006 - "In the present study, we aimed to investigate the effect and mechanism of YC-1 on HIF-1alpha in a hepatocellular carcinoma cell line under hypoxic condition, which was generated by incubating cells with 0.1% O(2). "
12/01/2007 - "Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma."
03/01/2005 - "YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells."
12/01/2007 - "The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivity of hepatocellular carcinoma (HCC). "

05/01/2012 - "In the current study, we investigated the targets of YC-1 and mechanism of its action in MDA-MB-468 breast cancer cells. "
05/01/2012 - "Our previous studies demonstrated that YC-1 inhibited breast cancer cell proliferation under normoxic conditions. "
09/01/2014 - "These data suggest that YC-1 is a potential anticancer drug candidate for triple-negative breast cancer."
09/01/2014 - "We discovered that YC-1 induces apoptosis and inhibits tumour growth of breast cancer cells via down-regulation of EZH2 by activating c-Cbl and ERK. "
09/01/2014 - "In breast cancer cells, YC-1 down-regulated EZH2 expression in a concentration- and time-dependent manner. "

09/15/2015 - "YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia."
09/15/2015 - "YC-1 significantly reduced sFlt-1 and sENG secretion from human umbilical vein endothelial cells, purified primary trophoblast cells and placental explants taken from patients with preterm preeclampsia. "
10/01/2013 - "Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model."
10/01/2013 - "The present study was designed to investigate the effects of YC-1, a nitric oxide (NO)-independent soluble guanylate cyclase (sGC) activator, and DEA/NO, a NO donor, on smooth muscle responses in the preeclampsia model with suramin-treated rats and on the levels of cyclic guanosine monophosphate (cGMP) of thoracic aorta rings isolated from term-pregnant rats. "

03/08/2002 - "These results suggest that YC-1 is a potent, physiologically active agent with major anti-proliferative and anti-platelet properties that may provide protection against vascular injury through cGMP-dependent mechanisms."
01/01/2004 - "The ability of YC-1 to prevent smooth muscle cell apoptosis may play an important role in blocking lesion formation at sites of vascular injury."